Tate & Lyle sweetener milestone: Tate & Lyle stock spans GBp 319.40 to GBp 650.00

Published on 10/15/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sweetener milestone reported October 8, 2026. Tate & Lyle stock costs EUR 6.68 on October 15, 2026, with GBP 2.5 billion market value.

Operating facts and valuation

BioHarvest and Tate & Lyle reported a sweetener milestone on October 8, 2026.
Fiscal year 2026 revenue reached GBP 2,006 million, while net income was GBP 97 million.
Tate & Lyle stock trades at EUR 6.68 at 1:04 p.m. CEST at Lang & Schwarz on October 15, 2026.
The market capitalization was GBP 2.5 billion as of October 15, 2026.

Aquarellmalerei der Londoner Skyline mit Themse und Brücken — Tate & Lyle PLC (GB0008707753) mit Hauptsitz in London, dargestellt als sanftes Aquarell der Themse-Skyline, Illustration mit AI erstellt.

Tate & Lyle (ISIN GB00BP92CJ43) was trading at EUR 6.68 at Lang & Schwarz on October 15, 2026, at 1:04 p.m. CEST. The company and BioHarvest Sciences reported a milestone in next-generation sweetener development on October 8, 2026, according to StockTitan.

Commercial-grade sweetener takes shape

The development program demonstrated that BioHarvest's Botanical Synthesis platform could produce the targeted sweetening solution. The October 8, 2026 filing said development activities continued in line with expectations and described the milestone as progress in the collaboration.

The announcement matters because it moves the project from platform potential toward a product specification that food and beverage manufacturers could evaluate. The filing also said the collaboration builds on an expanded arrangement announced in May 2026, while commercialization, customer adoption and revenue remain future steps.

What does the October 8 milestone mean?

The immediate investor takeaway is strategic rather than financial. Tate & Lyle is adding another option to its sweetening toolkit as customers seek sugar and calorie reduction solutions, but the announcement disclosed no revenue, order value or launch date for the new product.

The latest reported financial comparison provides a tougher operating backdrop. In fiscal year 2026, revenue stood at GBP 2,006 million, up 15.55 percent from GBP 1,736 million in fiscal year 2025, while net income fell 32.17 percent to GBP 97 million from GBP 143 million, according to Reuters. The contrast places greater weight on whether specialty ingredients and new product development can improve earnings quality.

Valuation and trading reference

Tate & Lyle's market capitalization was GBP 2.5 billion on October 15, 2026. Its London-listed shares had a 52-week range of GBp 319.40 to GBp 650.00, with the range and market value reported in the same market snapshot.

The current euro indication puts the German trading perspective alongside the company's London listing. Tate & Lyle was trading at EUR 6.68 at Lang & Schwarz on October 15, 2026, at 1:04 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Tate & Lyle stock.